These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24649797)

  • 1. [In vitro activity of sitafloxacin against clinical isolates in 2012].
    Amano A; Matsuzaki K; Kishi N; Koyama H; Hasegawa M; Ikeda F; Matsumoto T; Yamaguchi H; Okutani Y
    Jpn J Antibiot; 2013 Dec; 66(6):311-30. PubMed ID: 24649797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In vitro activity of sitafloxacin against clinical isolates in 2009].
    Amano A; Matsuzaki K; Kishi N; Saika T; Hasegawa M; Ikeda F; Matsumoto T; Yamaguchi H; Kanda Y; Shiozawa T
    Jpn J Antibiot; 2010 Dec; 63(6):411-30. PubMed ID: 21425595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of sitafloxacin against atypical bacteria (2009-2014) and comparison between susceptibility of clinical isolates in 2009 and 2012.
    Amano A; Kishi N; Koyama H; Matsuzaki K; Matsumoto S; Uchino K; Yamaguchi H; Yokomizo A; Mizuno M
    Jpn J Antibiot; 2016 Sep; 69(3):131-142. PubMed ID: 30226949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Susceptibility of clinically-isolated bacteria strains to respiratory quinolones and evaluation of antimicrobial agent efficacy by Monte Carlo simulation].
    Kosaka T; Yamada Y; Kimura T; Kodama M; Fujitomo Y; Masaki N; Toshiaki K; Keisuke S; Fujita N
    Jpn J Antibiot; 2016 Feb; 69(1):27-40. PubMed ID: 27290828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antibacterial activity of quinolones against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].
    Nakamura T; Shimizu C; Hirakawa K; Inui S; Okuda K; Nakata C; Fujimoto H; Okura H; Uemura Y; Takahashi H
    Jpn J Antibiot; 2009 Jun; 62(3):194-202. PubMed ID: 19882980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antimicrobial activity of oral quinolones against clinical isolates of Bifidobacterium group and Clostridium difficile].
    Kimura M; Yamagishi Y; Terada M; Ohki E; Tanaka K; Watanabe K; Mikamo H
    Jpn J Antibiot; 2010 Apr; 63(2):171-7. PubMed ID: 20919497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid bactericidal activity of sitafloxacin against Streptococcus pneumoniae.
    Kanda H; Inoue K; Okumura R; Hoshino K
    Jpn J Antibiot; 2013 Feb; 66(1):9-23. PubMed ID: 23777013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proposed Pharmacokinetic-Pharmacodynamic Breakpoint of Garenoxacin and Other Quinolones.
    Yamagishi Y; Shibata T; Nakagawa S; Nomura N; Mitsuyama J; Mikamo H
    Jpn J Infect Dis; 2017 Nov; 70(6):616-620. PubMed ID: 28890509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antimicrobial susceptibility surveillance of recent isolates from otorhinolaryngological infections to garenoxacin and other antimicrobial drugs].
    Suzuki K; Kurono Y; Kobayashi T; Nishimura T; Baba S; Harabuchi Y; Fujisawa T; Yamanaka N; Ubukata K; Ikeda F
    Jpn J Antibiot; 2009 Apr; 62(2):71-8. PubMed ID: 19673349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mutant prevention concentrations of garenoxacin against Streptococcus pneumoniae isolates from otorhinolaryngological infections].
    Suzuki K; Kurono Y; Kobayashi T; Nishimura T; Baba S; Harabuchi Y; Fujisawa T; Yamanaka N; Ubukata K; Ikeda F
    Jpn J Antibiot; 2010 Aug; 63(4):312-8. PubMed ID: 21298864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
    Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
    Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S; Ianniello F; Leone S; Esposito S
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination effect of antibiotics against bacteria isolated from keratitis using fractional inhibitory concentration index.
    Suzuki T; Ohashi Y
    Cornea; 2013 Jul; 32(7):e156-60. PubMed ID: 23665643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
    Tiengrim S; Phiboonbanakit D; Thunyaharn S; Tantisiriwat W; Santiwatanakul S; Susaengrat W; Srisurat N; Malithong A; Srisangchan P; Thamlikitkul V
    J Med Assoc Thai; 2012 Feb; 95 Suppl 2():S6-17. PubMed ID: 22574524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bactericidal activity of sitafloxacin and other new quinolones against antimicrobial resistant Streptococcus pneumoniae].
    Kobayashi I; Kanayama A; Hasegawa M; Kaneko A
    Jpn J Antibiot; 2013 Feb; 66(1):25-35. PubMed ID: 23777014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative bactericidal activity of four fluoroquinolones against Pseudomonas aeruginosa isolated from chronic suppurative otitis media.
    Ikeda K; Misawa S; Kusunoki T
    BMC Ear Nose Throat Disord; 2015; 15():5. PubMed ID: 26472937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,866 clinical isolates obtained from 72 centers in 2010].
    Yamaguchi K; Ohno A; Ishii Y; Tateda K; Iwata M;
    Jpn J Antibiot; 2012 Jun; 65(3):181-206. PubMed ID: 23173294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.
    Gales AC; Jones RN
    Diagn Microbiol Infect Dis; 2000 Jan; 36(1):19-36. PubMed ID: 10744364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2002)].
    Shimada K; Nakano K; Igari J; Oguri T; Ikemoto H; Mori T; Yokouchi H; Yamamoto M; Inoue H; Nakadate T; Suwabe A; Okada S; Ashino Y; Gejyo F; Okada M; Aoki N; Kitamura N; Suzuki Y; Karasawa Y; Nakata K; Nakatani T; Inagawa H; Kudo K; Kobayashi N; Tanaka T; Kobayashi H; Goto H; Kawai S; Takeda H; Sumitomo M; Matsushima T; Niki Y; Kohno S; Miyazaki Y; Yanagihara K; Hirakata Y; Matsuda J; Nasu M; Hiramatsu K; Suga M; Tosaka M
    Jpn J Antibiot; 2004 Jun; 57(3):213-45. PubMed ID: 15376784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients.
    Edmiston CE; Krepel CJ; Kehl KS; Seabrook GR; Somberg LB; Almassi GH; Smith TL; Loehrl TA; Brown KR; Lewis BD; Towne JB
    J Antimicrob Chemother; 2005 Nov; 56(5):872-8. PubMed ID: 16186167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.